CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML
HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a third-party to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible IDH1 mutation. The application is the first market filing for CStone since its inception in 2015. TIBSOVO is a first-in-class, oral, potent and selective inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. The TFDA awarded TIBSOVO the NDA filing priority review status on April 24, 2019.
Dr. Frank Jiang, CStone Chairman and CEO, commented: "The NDA filing for TIBSOVO in Taiwan is a significant milestone for the company. TIBSOVO has the potential to become our first commercial product, and CStone is now taking the first step towards becoming a commercial-stage company. There are no currently approved treatments for AML patients with IDH1 mutation in the Greater China region. We are already actively building a commercial team and will be fully committed to introducing this product to patients in Greater China as quickly as we can for the sufferers who otherwise would have no treatment options."
AML is the most common acute leukemia affecting adults and is characterized by rapid disease progression. There are approximately 20,000 new cases of AML in the U.S., with a five-year survival rate of 27%, as compared to over 30,000 annual cases in China and a five-year survival rate below 20%. The incidence rate in Taiwan is 4 per 100,000 people, equating to around 800 annual cases, with a five-year survival rate of 26%. The prognosis for elderly and R/R AML patients after current available treatment is poor and around 6%-10% of all AML cases have the IDH1 mutation.
Discovered by CStone's partner, Agios Pharmaceuticals, ivosidenib was first approved by the U.S. FDA for adults with R/R AML with an IDH1 mutation in 2018, and secured approval for a supplemental new drug application in 2019 for the treatment of newly diagnosed AML patients with an IDH mutation who are ≥ 75 years old or have comorbidities that preclude the use of intensive induction chemotherapy. The US FDA also granted Breakthrough Therapy Designation for ivosidenib in combination with Azacitidine for this population of newly diagnosed AML patients with an IDH mutation who are ≥ 75 years old or have comorbidities that preclude the use of intensive induction chemotherapy.
The efficacy of TIBSOVO® was evaluated in 174 adult patients with R/R AML with an IDH1 mutation. TIBSOVO® was given orally at a starting dose of 500 mg daily until disease progression, development of unacceptable toxicity, or undergoing hematopoietic stem cell transplantation. Trial data to support filing showed that TIBSOVO as a monotherapy to treat R/R AML patients with an IDH1 mutation achieved complete remission (CR) and complete remission with partial hematologic improvement (CRh) rate of 32.8% (57 of 174 patients) (95% CI: 25.8, 40.3). The median duration of CR+CRh is 8.2 months (95% CI: range 5.6, 12 months).
The safety profile of single-agent TIBSOVO® was evaluated in 179 patients with R/R AML with an IDH1 mutation treated with a dose of 500 mg daily. The median duration of exposure to TIBSOVO® was 3.9 months (range 0.1 to 39.5 months). In the clinical trial, 19% (34/179) of patients treated with TIBSOVO® experienced differentiation syndrome, which can be fatal if not treated. QTc interval prolongation and Guillain-Barré Syndrome occurred in patients treated with TIBSOVO®. The most common adverse reactions (≥20%) of any grade were fatigue, leukocytosis, arthralgia, diarrhea, dyspnea, edema, nausea, mucositis, electrocardiogram QT prolonged, rash, pyrexia, cough and constipation. The most frequent serious adverse reactions (≥5%) were differentiation syndrome (10%), leukocytosis (10%) and electrocardiogram QT prolonged (7%).
In June 2018, CStone and Agios announced an exclusive collaboration and license agreement for the development and commercialization of TIBSOVO in Mainland China, Hong Kong, Macau and Taiwan (Greater China).
About TIBSOVO (ivosidenib)
TIBSOVO (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated in the United States as a treatment for AML with a susceptible IDH1 mutation under the following conditions:
- In patients with newly diagnosed IDH1-susceptible AML who are ≥ 75 years old or have comorbidities that preclude the use of intensive induction chemotherapy.
- In adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test.
CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and molecularly-targeted drugs to address unmet medical needs for cancer patients in China and worldwide. Since the Company's inception in 2015, CStone has assembled a world-class management team that has a full spectrum of complementary skillsets from preclinical research to clinical development and commercialization. With combination therapies as a core strategy, the Company has built a rich oncology pipeline of 15 oncology drug candidates. Currently five late-stage drug candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model, and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative and differentiated oncology therapies to cancer patients worldwide.
For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com.
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
SOURCE CStone Pharmaceuticals